Caris Life Sciences and Syapse will collaborate to collect and combine molecular and genomic information with clinical treatment and outcomes data across the Caris Centers of Excellence for Precision Medicine Network.
Integration of Caris Molecular Intelligence, Caris’ panomic, comprehensive tumor profiling service, with the Syapse Precision Medicine Platform , will provide a powerful real-time, point-of-care, clinical decision support system to enable more informed treatment decisions for each individual patient. Participating COE Network sites can use the integrated decision support system, and may use Syapse to further support their complete precision medicine workflows.
Caris Molecular Intelligence uses multiple technology platforms, including a proprietary 592-gene Next-Generation Sequencing panel with full gene coverage to assess point mutations, indels, and copy number variations, alongside RNAseq, for select gene fusions, in addition to Immunohistochemistry, in situ hybridization, and other platforms.
“We expect to profile 50,000 to 100,000 cancer patients annually across the COE Network. This is the largest oncology focused effort to combine comprehensive genomic and molecular profiling information with clinical outcomes data,” said David Halbert, chairman and CEO of Caris Life Sciences.
